Cargando…

Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma

Clear cell sarcoma (CCS) is an aggressive type of soft tissue tumor that is associated with high rates of metastasis. In the present study, we found that CPI-613, which targets tumorous mitochondrial energy metabolism, induced autophagosome formation followed by lysosome fusion in HS-MM CCS cells in...

Descripción completa

Detalles Bibliográficos
Autores principales: Egawa, Yuki, Saigo, Chiemi, Kito, Yusuke, Moriki, Toshiaki, Takeuchi, Tamotsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991736/
https://www.ncbi.nlm.nih.gov/pubmed/29879220
http://dx.doi.org/10.1371/journal.pone.0198940
_version_ 1783329894624657408
author Egawa, Yuki
Saigo, Chiemi
Kito, Yusuke
Moriki, Toshiaki
Takeuchi, Tamotsu
author_facet Egawa, Yuki
Saigo, Chiemi
Kito, Yusuke
Moriki, Toshiaki
Takeuchi, Tamotsu
author_sort Egawa, Yuki
collection PubMed
description Clear cell sarcoma (CCS) is an aggressive type of soft tissue tumor that is associated with high rates of metastasis. In the present study, we found that CPI-613, which targets tumorous mitochondrial energy metabolism, induced autophagosome formation followed by lysosome fusion in HS-MM CCS cells in vitro. Interestingly, CPI-613 along with chloroquine, which inhibits the fusion of autophagosomes with lysosomes, significantly induced necrosis of HS-MM CCS cell growth in vitro. Subsequently, we established a murine orthotropic metastatic model of CCS and evaluated the putative suppressive effect of a combination of CPI-613 and chloroquine on CCS progression. Injection of HS-MM into the aponeuroses of the thigh, the most frequently affected site in CCS, resulted in massive metastasis in SCID-beige mice. By contrast, intraperitoneal administration of CPI-613 (25 mg/kg) and chloroquine (50 mg/kg), two days a week for two weeks, significantly decreased tumor growth at the injection site and abolished metastasis. The present results imply the inhibitory effects of a combination of CPI-613 and chloroquine on the progression of CCS.
format Online
Article
Text
id pubmed-5991736
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59917362018-06-15 Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma Egawa, Yuki Saigo, Chiemi Kito, Yusuke Moriki, Toshiaki Takeuchi, Tamotsu PLoS One Research Article Clear cell sarcoma (CCS) is an aggressive type of soft tissue tumor that is associated with high rates of metastasis. In the present study, we found that CPI-613, which targets tumorous mitochondrial energy metabolism, induced autophagosome formation followed by lysosome fusion in HS-MM CCS cells in vitro. Interestingly, CPI-613 along with chloroquine, which inhibits the fusion of autophagosomes with lysosomes, significantly induced necrosis of HS-MM CCS cell growth in vitro. Subsequently, we established a murine orthotropic metastatic model of CCS and evaluated the putative suppressive effect of a combination of CPI-613 and chloroquine on CCS progression. Injection of HS-MM into the aponeuroses of the thigh, the most frequently affected site in CCS, resulted in massive metastasis in SCID-beige mice. By contrast, intraperitoneal administration of CPI-613 (25 mg/kg) and chloroquine (50 mg/kg), two days a week for two weeks, significantly decreased tumor growth at the injection site and abolished metastasis. The present results imply the inhibitory effects of a combination of CPI-613 and chloroquine on the progression of CCS. Public Library of Science 2018-06-07 /pmc/articles/PMC5991736/ /pubmed/29879220 http://dx.doi.org/10.1371/journal.pone.0198940 Text en © 2018 Egawa et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Egawa, Yuki
Saigo, Chiemi
Kito, Yusuke
Moriki, Toshiaki
Takeuchi, Tamotsu
Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma
title Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma
title_full Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma
title_fullStr Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma
title_full_unstemmed Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma
title_short Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma
title_sort therapeutic potential of cpi-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991736/
https://www.ncbi.nlm.nih.gov/pubmed/29879220
http://dx.doi.org/10.1371/journal.pone.0198940
work_keys_str_mv AT egawayuki therapeuticpotentialofcpi613fortargetingtumorousmitochondrialenergymetabolismandinhibitingautophagyinclearcellsarcoma
AT saigochiemi therapeuticpotentialofcpi613fortargetingtumorousmitochondrialenergymetabolismandinhibitingautophagyinclearcellsarcoma
AT kitoyusuke therapeuticpotentialofcpi613fortargetingtumorousmitochondrialenergymetabolismandinhibitingautophagyinclearcellsarcoma
AT morikitoshiaki therapeuticpotentialofcpi613fortargetingtumorousmitochondrialenergymetabolismandinhibitingautophagyinclearcellsarcoma
AT takeuchitamotsu therapeuticpotentialofcpi613fortargetingtumorousmitochondrialenergymetabolismandinhibitingautophagyinclearcellsarcoma